A Search Service for Abbreviation / Long Form

â–  Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 28
[Display Entries]
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : LAMA
Long Form : long-acting muscarinic receptor antagonist
No. Year Title Co-occurring Abbreviation
2021 Are COPD Prescription Patterns Aligned with Guidelines? Evidence from a Canadian Population-Based Study. COPD, OR
2021 Escalation Time to Open Triple Combination Therapy from the Initiation of LAMA versus ICS/LABA in COPD Management: Findings from Comparing the Incidence of Tiotropium and ICS/LABA in Real-World Use in South Korea (CITRUS) Study. CI, COPD, HR, ICSs, LABA
2021 Triple therapy in uncontrolled asthma: a network meta-analysis of phase III studies. FDC, HD, ICS, LABA, MD
2020 Deciphering patterns of respiratory medication use in Ireland to target interventions appropriately: a focus on COPD. ---
2020 Efficacy and safety of revefenacin for nebulization in patients with chronic obstructive pulmonary disease taking concomitant ICS/LABA or LABA: subgroup analysis from phase III trials. COPD, FEV1, ICS, LABA, LABA, LS, SGRQ
2020 New Perspectives for Mucolytic, Anti-inflammatory and Adjunctive Therapy with 1,8-Cineole in COPD and Asthma: Review on the New Therapeutic Approach. BUD, COPD, IL, IRF3, LPS, NF-kappaB, ROS, SOD, TNF-alpha
2019 Adding a LAMA to ICS/LABA Therapy: A Meta-analysis of Triple Combination Therapy in COPD. AECOPD, ICS, LABA, SAEs
2019 Comparative Causal Analysis of the Effects of Long-Acting Muscarinic Antagonist Versus No Long-Acting Bronchodilator Use on Readmission or Mortality After Hospitalization for Chronic Obstructive Pulmonary Disease. CI, HR, IPTW
2019 Trends in prescriptions and costs of inhaled medications in chronic obstructive pulmonary disease: a 19-year population-based study from Canada. COPD, ICS, LABA, SABA, SAMA
10  2018 Single-inhaler triple therapy utilizing the once-daily combination of fluticasone furoate, umeclidinium and vilanterol in the management of COPD: the current evidence base and future prospects. COPD, ICS, LABA
11  2017 Characterisation of a murine model of the late asthmatic response. AHR, LAR
12  2017 Combination of glycopyrronium and indacaterol inhibits carbachol-induced ERK5 signal in fibrotic processes. alpha-SMA, CCh, COPD, ERK5, TGF-beta1
13  2017 Tolerability of Bisoprolol on Domiciliary Spirometry in COPD. ICS, LABA
14  2016 Aclidinium bromide inhalation powder for the long-term, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease including chronic bronchitis and emphysema. ---
15  2016 Cost-effectiveness of combination therapy umeclidinium/vilanterol versus tiotropium in symptomatic COPD Spanish patients. FEV1, ICER, NHS, PSA, QALYs, TIO, UMEC/VI
16  2016 Long acting muscarinic antagonists for the treatment of chronic obstructive pulmonary disease: a review of current and developing drugs. COPD, MABA
17  2016 Triple inhaled therapy for chronic obstructive pulmonary disease. ACOS, COPD, FDC, ICS, LABA
18  2015 Bronchodilating drugs for chronic obstructive pulmonary disease: current status and future trends. COPD, FDCs, LABA, MABA
19  2015 Pharmacologic rationale underlying the therapeutic effects of tiotropium/olodaterol in COPD. COPD
20  2015 Pharmacologic rationale, efficacy and safety of the fixed-dose co-formulation of indacaterol and glycopyrronium. COPD
21  2015 The statement of the Polish Society of Allergology experts on the treatment of difficult-to-treat asthma. GINA
22  2014 QVA149 (indacaterol/glycopyrronium fixed-dose combination): a review of its use in patients with chronic obstructive pulmonary disease. COPD, FLAME, LABA
23  2014 Umeclidinium for the treatment of chronic obstructive pulmonary disease. COPD, FEV1, LABA
24  2013 Inhaled glycopyrronium bromide: a review of its use in patients with moderate to severe chronic obstructive pulmonary disease. COPD
25  2013 Long-acting beta-agonists and their association with inhaled corticosteroids in COPD. COPD
26  2013 Safety, tolerability, pharmacodynamics and pharmacokinetics of umeclidinium and vilanterol alone and in combination: a randomized crossover trial. COPD, nDPI, PD, PK
27  2013 â–¾Glycopyrronium for COPD. COPD
28  2012 A randomized, double-blind dose-ranging study of the novel LAMA GSK573719 in patients with COPD. ---